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Metabolic programming and metabolic imprinting describe early life events, which impact upon on later physiological outcomes.
Despite the increasing numbers of papers and studies, the distinction between metabolic programming and metabolic imprinting
remains confusing. The former can be defined as a dynamic process whose effects are dependent upon a critical window(s)
while the latter can be more strictly associated with imprinting at the genomic level. The clinical end points associated with
these phenomena can sometimes be mechanistically explicable in terms of gene expression mediated by epigenetics. The predic-
tivity of outcomes depends on determining if there is causality or association in the context of both early dietary exposure and
future health parameters. The use of biomarkers is a key aspect of determining the predictability of later outcome, and the strengths
of particular types of biomarkers need to be determined. It has become clear that several important health endpoints are impacted
upon by metabolic programming/imprinting. These include the link between perinatal nutrition, nutritional epigenetics and
programming at an early developmental stage and its link to a range of future health risks such as CVD and diabetes. In some
cases, the evidence base remains patchy and associative, while in others, a more direct causality between early nutrition and
later health is clear. In addition, it is also essential to acknowledge the communication to consumers, industry, health care providers,
policy-making bodies as well as to the scientific community. In this way, both programming and, eventually, reprogramming can
become effective tools to improve health through dietary intervention at specific developmental points.
Imprinting or programming as a result of early life experience
is becoming an accepted scientific phenomenon. Implicit in
this is the concept of a ‘stage of developmental plasticity,
where specific conditions give rise to later life outcomes’.
The most significant aspect is metabolic imprinting, in
which maternal undernutrition, obesity and diabetes during
gestation and lactation can contribute towards obesity in the
offspring(1). Other endpoints that seem to be affected by
early life exposure include neurodevelopment and immune
modulation.
The concept of fetal growth affecting adult disease was
explained by Barker(2,3) in his seminal papers. Programming
later evolved to mean alterations in nutrition and growth at
specific developmental points, resulting in long-term or even
permanent effects(4).
Observation is the first step and the initial link between
health and early diet is often found from epidemiological
investigations. One of the most exemplary studies is the
Avon Longitudinal Study of Parents and Children
(ALSPAC) cohort(5). This has been the source for a host of
publications in which early diet is linked to later obesity and
to other health endpoints, as outlined in Table 1.
Other cohorts include the Helsinki study, which
showed a link between prenatal and postnatal factors and
type 2 diabetes(6), diet in pregnancy and blood pressure of
offspring(7), maternal nutritional status and blood pressure(8)
and the USA National Children’s Study. This latter study is
designed to examine the effects of environmental influences
on the health and development of 100 000 children across
the USA, following them from before birth until age 21.
The goal of the study is to improve the health and well-
being of children by assessing the impact of exposure on
health endpoints. These and other studies are presented in
more detail in section ‘Nutritional epigenomics: how to
make sense of what we measure’.
These and other observational studies can be misinterpreted
due to confounders; however, they can help to establish
associations, which can then be tested by intervention to
demonstrate the causality. The observational evidence has
been the starting point for the scope of review since it provides
a strong suggestion of a measurable effect apparently linked to
an earlier exposure. However, while numerous studies have
been carried out using animal models – particularly in relation
to obesity – for obvious reasons, human clinical interventions
are comparatively rare.
Another crucial element in considering long-term results
from early exposure is the timeframe/timing and duration of
exposure. In many cases, the potential long-term effect of a
single intervention is greatest in the developing system
(infant or fetus), and the size of the effective dose may be rela-
tively low. However, the ability to predict the precise effect of
the intervention in terms of long-term outcome is also low.
In adults, the opposite is often the case. The dietary interven-
tion may have to be significant and the prediction of effect is
immediately measurable but the long-term effect of a single
intervention is low as demonstrated conceptually in Fig. 1.
A further complication is that clinical endpoints change
with time and often the effects of the initial programming
event may be significantly diluted by a lifetime exposure to
a range of other factors. This, together with reducing meta-
bolic plasticity and increased differentiation, may be a major
factor in the lowering of programming potential as cells and
organisms get older (Fig. 2).
In mechanistic terms, it has been hypothesised that fetal
developmental plastic responses can cause changes in
lean body mass, endocrinology, blood flow and vascular
loading. These responses are then modulated or amplified
in infancy and childhood and therefore lead to increased
susceptibility– particularly to cardiovascular and metabolic
disease – in adulthood(9). In developmental terms, fetal
exposure to a range of dietary components including Ca,
folate, Mg, high or low protein and Zn as a result of maternal
diet have all been, with varying degrees of confidence, associ-
ated with birth weight. Low birth weight is by itself associated
with a range of long-term outcomes, including insulin resist-
ance and type 2 diabetes in later life.
A further addition to the genre was the use of the term
‘metabolic imprinting’ which was adopted by Waterland &
Garza(10), who suggested that while biological mechanisms
exist to ‘memorise’ the metabolic effects of early nutrient
exposure, these were not hypothesis driven. They proposed
to apply more rigour to the testing of chronic disease out-
comes and on the development of biological mechanisms
and the testing of hypotheses. Metabolic imprinting was
defined as ‘the basic biological phenomena that putatively
underlie the relations among nutritional experiences of early
life and later diseases’.
The authors also considered that metabolic programming,
while being a useful term, did not convey with sufficient
clarity the key aspects of imprinting which, as they saw it,
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was required to encompass both susceptibility limited to a
specific developmental window and a persistent effect lasting
through adulthood – although it is not clear if the magnitude of
the effect should be consistent through adulthood or if a
falling off in potency is acceptable.
They also considered that the outcome should be specific
and measurable and that a dose–response or threshold relation
between a specific exposure and an outcome should be demon-
strable. Waterland & Garza(10) also distinguished between
other types of imprinting (e.g. hormonal and metabolic).
The essence of their argument appears to be that ‘imprinting’
has particular characteristics and the term can be used in con-
junction with several prefixes dependent upon the target phys-
iological effect but that in each case there should be
a mechanistic underpinning for the use of the term.
Following this suggestion, Lucas(11) raised some questions
as to the use of the term ‘imprinting’. His main argument
was that programming can encompass a wide range of biologi-
cal effects, whereas imprinting had a much narrower range.
In addition, he also felt that the use of a term more usually
associated with a quite distinct event – i.e. gene imprinting,
would inevitably lead to confusion. Since this early exchange,
a plethora of papers have appeared which seem to use the
terms imprinting and programming almost interchangeably.
This is not a particularly helpful situation for communication
to both scientific and non-scientific stakeholders and a robust
and reliable definition is a prerequisite to developing the area.
Epigenetics, on the other hand, has been quite strictly
defined in terms of specific molecular events relating to
gene expression and provides a mechanistic underpinning
for many imprinting/programming events. The development
of clear mechanisms to explain the impact of early life
exposure on later clinical endpoints would be of great value
in predicting the outcomes of specific dietary interventions.
The scope of this review is to lay the foundation for the
prioritisation of factors that determine the relative significance
of different early exposures in terms of health outcomes.
These outcomes should include both mortality and morbidity
or quality of life. In this way, we can enumerate the most sig-
nificant risk factors associated with the early life events and
define the causality, association and effects. In particular, to
provide a guide for scientists, regulators and policymakers
that will enable them to understand what is presently
known, prioritise the research to address the gaps and effec-
tively impact upon public health in an understandable and
targeted way. Implicit in this analysis is a realisation of the
social conditions that pertain to early life exposure and later
health and consequences for funding prioritisation.
Enabling technologies and methodology
Biomarkers – what to measure
Biological systems are constantly in a state of flux both due
to internal interactions and due to external exposures. In the
context of diet and health, biomarkers are factors that reflect
biological status at a given time point. For example, dietary
stanols and sterols will reduce cholesterol levels in hypercho-
lesterolaemic individuals. High cholesterol is a risk factor for
CVD; therefore, blood cholesterol is a biomarker which
reflects the increased risk of a disease outcome and may be
affected by a specific dietary intervention. Most biomarkers
measure biological response at a specific time point and
hence the effect of a given intervention at that time point
also. Finding relevant, predictive biomarkers related to
programming or imprinting is not straightforward. The bio-
logically relevant event remains significant long after the
exposure responsible for it has ceased. Finding biomarkers
that are not only predictive of a later effect but which,
under the best circumstances, remain measurable once the
initial exposure has ceased constitutes a major problem.
This will become clear when we consider definitions of
biomarkers, their validation and how they can best be used.
Biomarkers have conveniently been divided into sub-
categories(12). The definitions are designed to allow for a
Table 1. Correlations between early exposure and later health outcomes from the Avon longitudinal study of parents and
children cohort
Dietary exposure Health endpoint References
Infant feeding method Obesity Toschke et al.(25)
Seafood consumption in pregnancy Neurodevelopmental outcomes Hibbeln et al. and Daniels et al.(243,244)
Dietary energy intake at 4 months Postnatal weight gain and childhood BMI Ong et al.(245)
Insulin-like growth factor-1 levels Intelligence quotient at 9 years Gunnell et al.(246)
Prenatal paracetamol exposure Asthma and atopy Shaheen et al.(247)
Soya protein and peanut oil exposure Peanut allergy Lack et al.(248)
Early rate of weight gain Diabetes, insulin resistance Ong & Dunger(249)
Maternal mineral and folate intake Bone health Tobias et al.(220)
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Fig. 1. Conceptual figure on the effects of exposure at different developmental
ages. , predictive power; , intervention; , long-term effect.
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simple categorisation but it also tends to describe the analyti-
cal methodology used. In addition, it also introduces the
concepts of surrogate biomarkers and predictivity.
Exposure. A biomarker of exposure can be defined as a
chemical entity (or something derived directly from it),
which is measurable in an exposed individual and reflecting
that exposure in a dose-dependent fashion. The simplest
exposure biomarkers are the components of interest them-
selves. It is implicit in this type of measurement that the
component is either unchanged by metabolism or can be con-
verted into something that is directly measurable.
Since programming implies some alteration in status,
exposure biomarkers are only relevant to programming if
they are associated with a known and measurable effect in a
time period after exposure. The measurement taken early in
life may provide useful information concerning the likelihood
of a subsequent health endpoint once the exposure has ceased.
Observational studies such as ALSPAC in which a specific
exposure is correlated with later outcomes are valuable since
they can lead to the development of hypothesis-driven
research. Many such studies reveal correlations rather than
causal associations and this is an inherent weakness of this
type of investigation. The utility of biomarkers of exposure
in the context of programming is where they are linked to
mechanistic or associative knowledge of the consequences
of that exposure. The great advantage of developing robust
biomarkers of exposure is that they are measurable events at
a time when it is possible to change the outcome by dietary
manipulation. A typical exposure biomarker could include
the levels of dioxins whose presence in the body is reflective
of earlier exposure.
Susceptibility. A biomarker of susceptibility has trad-
itionally largely encompassed genetic polymorphisms or
variability that give rise to an increased susceptibility to an
effect. This can be a direct (genetic) or an indirect effect.
The implication is that a biomarker of genetic variability is
a distinct and measurable entity in a gene which can be
used to predict likely outcomes. Such genes are referred to
as ‘imprinted’ genes.
More recently, susceptibility has grown to include epige-
netic effects where there is a connection between certain
genes, exposure to some environmental (including dietary)
factors and later biological events. For example, folate
deficiency affects epigenetic events and has been implicated
in colon cancer susceptibility. This led to the conclusion that
‘the portfolio of evidence from animal, human and in vitro
studies suggests that the effects of folate deficiency and sup-
plementation on DNA methylation are gene and site specific,
and appear to depend on cell type, target organ, stage of trans-
formation and the degree and duration of folate depletion’(13).
In these terms, susceptibility is not fixed but is measurable at a
specific time. It therefore becomes a fluid and dynamic pro-
cess which is affected by external factors and may change
depending on when in the temporal sequence it is measured.
Effect. Biomarkers of effect comprise the most challen-
ging group. In order for a biomarker of effect to be useful
in the context of programming, it must fulfil some key criteria.
(1) It should be measurable at a time point when it is able to
be altered by an external (dietary) component and that
alteration should be reflective of an eventual changed
health endpoint. Biomarkers of effect in general may be
measured at a time that is distant from the exposure
and can also be as a result of cumulative exposure (e.g.
DNA damage). However, in order to be relevant to pro-
gramming, an effect biomarker must be predictive of a
future outcome. It should be measurable before and
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Fig. 2. The shrinking of unmodified endpoints and increase in environmentally modified endpoints over time as external factors impact through a lifetime.
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after the exposure event and should predict the biological
outcomes.
(2) There must be a dose-related, mechanistic rationale
between exposure (and a biomarker of exposure) and
the biomarker of effect and to the health endpoint. This
means that many biomarkers of effect are measuring
surrogate endpoints.
(3) In common, with all biomarkers, it must be validated both
in terms of analytical methodology and biological
integrity.
Many of the biomarkers of effect and exposure and their
relationship to eventual health outcomes have been indicated
in the first instance by prospective epidemiological studies.
These have suggested associations between certain events
and later onset of disease. While these are certainly useful
in suggesting new potential areas for study, it is important
to recognise that such studies have a high tendency to being
blurred by confounders, and the search for a mechanistic
underpinning may be futile.
Specificity of human/animal models
Research into developmental programming of adult health and
disease has made considerable progress over the past two dec-
ades but a clear consensus on the exact nutrients involved and
their mechanisms remains to be established. This problem
relates in part to the long-term developmental time frame in
which changes in metabolism and cardiovascular function
occur. At the same time, the discipline has had to contend
with the dual challenges of integrating findings from lifelong
epidemiological studies which have largely focussed on birth
weight and its relationship (or otherwise) with adult disease
and our ability to incorporate these results into appropriate
nutritional intervention studies using animal models. It is
now established that there are many potential influences on
offspring outcome. For example, maternal body composition,
age and parity, genetic constitution, macro and micronutrient
intake and handling, size, shape and number of offspring,
sex, type of lactation and so on.
In this section, we attempt to provide an overview of some
of the major problems with both human and animal studies in
conjunction with optimal experimental paradigms that may be
utilised in future research aimed at elucidating the precise
mechanisms by which changes in the maternal diet during
reproduction can impact on the life time health of resulting
offspring. Particular emphasis will be given to the applica-
bility of the animal model that has been utilised and how simi-
larities in the reproductive process may enable its best use in
future examinations of the nutritional programming of adult
health and disease.
Human models – historical and contemporary models of
developmental programming. The majority of the early
work conducted by David Barker and colleagues utilised
data from historical cohorts born in the 1930 s and benefited
from the meticulous birth records, often kept by the same
individual over long periods of time(13). This enabled clear
relationships between the size, shape and placental mass of
an infant at birth with hypertension later in life(14).
Subsequently, the recruitment of long-term historical records
from Finland has enabled longitudinal studies on infant
growth to be related to adult insulin sensitivity(15). More
recently, the use of nutritional interventions of preterm
formula in randomised controlled studies has emphasised the
impact of inappropriate growth in early infancy on later
disease risk(16). What is apparent, however, from more con-
temporary studies and the rise in both childhood and adult
obesity is the complexity of this process and how changes in
both activity and dietary intake make the translation of
findings from such studies into present lifestyle interventions
very difficult. At the same time, the causes of the ongoing
epidemic of obesity and the predicted increase in associated
renal and CVD are multifactorial(17) and these may be either
exacerbated or reduced by early dietary exposure(18).
Critical developmental stage. One consistent theme that is
apparent from both historical and contemporary studies is that
changes in nutrition at specific stages of pregnancy can have
very different outcomes(19). This is not unexpected as different
organs have critical and precise developmental stages which
may be compromised, or enhanced, and, thereafter, be perma-
nently set for the rest of that individual’s life. Importantly,
adaptations of this type appear to be dependent not only on
the period in which the mother’s diet is altered but also on
the diet to which she is rehabilitated(20). One fundamental
consideration is the self-limitation in food intake between
early and mid gestation that occurs commonly as a result of
nausea affecting approximately 90 % of women in the UK
that may be directly linked to Western diets(21). The extent
to which this directly relates to changes in placental function
and/or fetal growth remains less clear but there is a need to
match global prenatal and postnatal nutritional requirements
so as to avoid accelerated growth (during pregnancy and
early infant life)(22) and the concomitant increased risk of
later obesity and metabolic complications(23). Importantly,
however, intergenerational acceleration mechanisms do not
appear to make an important contribution to levels of child-
hood BMI within the population(24).
The lactational environment and postnatal development. A
further area requiring consideration is the relationship between
the maternal diet in late pregnancy, its impact on mammary
gland development and milk production and whether the
infant is breast-fed or formula fed(25). A higher macronutrient
content of formula feed compared with breast milk, in
conjunction with its fixed composition throughout a feed –
unlike in breast-fed infants for whom milk composition changes
with time – will impact on nutrient supply to the infant. It is,
therefore, not only the short-term but also the long-term advan-
tages of breast-feeding in terms of development of appetite
regulation that should be considered in this regard(26). The
type of lactation also impacts on other behavioural aspects,
including sleep–wake activity cycles(27), so that extended
breast-feeding may not only be beneficial in developing
countries but also in developed countries(28). Other confound-
ing factors such as social class and smoking during pregnancy
and lactation further determine postnatal diet(29).
In summary, the relationship between nutrient supply and
the key stages of development from the time of conception
to weaning is highly complex and requires careful, in-depth
consideration. It is necessary to conduct detailed animal
experiments in a range of species in order to elucidate
the mechanisms involved, be they epigenetic or related
processes(30).
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Classic animal models of nutritional programming. The
main animal models that have been utilised to date to investi-
gate the impact of maternal diet on long-term programming
have been rats and sheep(31). These obviously have very
different developmental patterns in not only the relationship
between placental and fetal growth but also in maturity at
birth and milk composition(32). The advantage of using rats
is their very short gestational length. However, the type of
diet they consume in the wild is very different to that fed to
housed laboratory animals in which semi-purified diets are
the norm. Such diets provide substantially greater nutrients
to pregnant rats than to controls, and thus should be con-
sidered ‘pharmalogical’ as opposed to ‘physiological’ and
are well outside the normal distribution. For example, in the
case of high-fat diets, these contain four times as much fat
compared with control diets and are at risk of being deficient
in micronutrients. Not surprisingly, when fed a diet so rich in
fat, maternal food intake is reduced(33). In addition, rats exhi-
bit coprophagia which has a substantial effect on nutrient flux
and the ability to experimentally manipulate the intake of
specific nutrients. It should be noted, however, that recent
rodent models have been developed to overcome the issue
of high fat content at the expense of other essential nutrients.
Appreciable placental growth continues up to term in the rat
which is necessary in part to meet the much higher protein
demands for fetal growth compared with that seen in human
subjects or sheep(34). In large mammals, the maximal period
of placental growth is early in pregnancy and is normally
necessary to meet the increased fetal nutrient requirements
in late gestation when fetal growth is exponential(35). Further-
more, rats produce large litters whereas sheep and human
subjects normally produce only one (or two) offspring of com-
parable birth weight per pregnancy.
Methodological considerations and the interpretation of
metabolic programming in rat and sheep models. There
have been two major problems with rat studies with regard
to assessment of the long-term cardiovascular outcomes.
First, in many studies, blood pressure has only been measured
using the tail-cuff technique in restrained and heated animals
during the day when they are normally inactive(36). The results
with this method differ considerably from those obtained from
telemetry(37). The tail-cuff method was originally validated
and recommended to use only in hypertensive animals(38).
Modest differences in blood pressure recorded in normoten-
sive rats are not always informative, which may explain
why, in more recent studies, offspring born to dams fed a
low-protein/high-carbohydrate diet through pregnancy show
either no difference or a reduction in blood pressure when
measured using either a telemetry or an indwelling arterial
catheter(39,40). Comparable findings are seen in offspring
born to dams in which food intake is reduced by 50 % through
pregnancy compared with controls(41). There also appears to
be a marked divergence in the long-term outcomes between
sexes in rats that is primarily linked to the faster, as well as
continued, growth of males compared with females(35).
Despite the fact that sheep are ruminants, they have proved
valuable in enabling us to understand the nutritional and
endocrine regulation of placento-fetal development. Like in
human subjects, the primary metabolic substrate for fetal
metabolism is glucose, for which GLUT 1 is the main
placental regulator(42). Glucose is, thus, transported across
the placenta by active diffusion determined by its concen-
tration in maternal blood(43). In addition, not only does
kidney development show a very similar ontogeny between
sheep and human subjects, but the distribution of total
nephrons across the adult population is also comparable(44).
It is also feasible to obtain very consistent blood pressure
recordings in the offspring using arterial cannulation while
the animal is standing freely with continual access to its
diet(45). At the same time, there is no discernable difference
in blood pressure control or glucose regulation between
sexes when measured in intact adult sheep(22,44).
In summary, the use of both rats and sheep as models for
examining the long-term effects of early nutritional interven-
tions is valid and can produce consistent results. Extrapolation
of these to the human situation must be carried out with care
and with a clear understanding of the discrepancies of both
model systems.
Other models
Preterm infants. Preterm-born babies may represent a human
model of the third trimester of pregnancy in which the impact
of the environment including nutrition can be studied.
Although the precise nutritional needs of the fetus to support
optimal growth velocity are not known, for instance, amino
acid and long-chain PUFA (LCPUFA) supplementation have
been shown to improve the early weight gain and/or body
composition, respectively(46 – 48). However, exposure to other
environmental factors associated with being born preterm
including high risk of infection and other non-nutritional
factors does complicate this further.
Thus, suitable nutritional interventions may now be avail-
able that can examine the relevant short- and long-term
outcomes in a consistent and validated manner to determine
how contemporary diets impact on fat deposition, metabolic
homoeostasis and cardiovascular control in animal models.
The completion of such studies may enable us to determine
the optimum nutrition in terms of quantity and quality. How-
ever, as Table 2 demonstrates nutritional interventions, even to
demonstrate short-term effects, must control for potential con-
founders and demonstrate the importance of sound interven-
tion design in this growing field.
Nutritional epigenomics: how to make sense of what we
measure
Slowing down or preventing the alarming progression of
obesity worldwide represents a major public health challenge
and a major health concern for future generations. The
presence of a heritable or familial component of susceptibility
to obesity is well established(49). However, apart from extre-
mely rare cases of monogenic forms, most cases correspond
to a multifactorial disorder(50). This said, however, obesity is
a good example of epigenetics as these common forms are
associated with a range of genetic and non-genetic familial
factors, triggered by the ‘developmental origins of disease’
phenomenon and aggravated by environmental factors, as
shown by the rate of discordance between monozygotic
twins(51,52). Epigenetic misprogramming during development
is now widely thought to have a persistent effect on the
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health of the offspring and may even be transmitted to the next
generation(53).
The term ‘epigenetics’ has been defined as ‘the causal inter-
actions between genes and their products which bring
phenotype into being’(54). It is now used to refer to stably
maintained mitotically (and potentially meiotically) heritable
patterns of gene expression occurring without changes in
DNA sequence. Mechanistically, this is achieved by a range
of modifications, including DNA methylation and a complex
repertoire of histone modifications: acetylation, methylation,
phosphorylation, ADP ribosylation, ubiquitination leading to
chromatin remodelling. These processes add to the informa-
tion of the underlying genetic code conferring unique tran-
scriptional instructions. Epigenetics instructions and machinery
create a dynamic nuclear environment that specifies transcrip-
tional states and comprises the essential components of
heritable cellular memory, a hallmark of differentiation.
Despite sequencing of the human genome studies of the
finely tuned chromatin epigenetic networks, DNA methylation
and histone modifications are required to determine how the
same DNA sequence generates different cells, lineages,
organs and ultimately the phenotype.
The mechanism of epigenetic manipulation. DNA methyl-
ation patterns and histone modifications are responsive to the
environment throughout the life. The epigenetic landscapes
are affected by environmental and genetic influences such as
embryo culture conditions, DNA methyltransferase 1 overex-
pression, hyperhomocysteinaemia and folate deficiency
either before or during pregnancy, in the postnatal and post-
weaning period that persist into adulthood. Transient nutri-
tional stimuli occurring at critical ontogenic stages may
have long-lasting influences on expression of various genes
by interacting with epigenetic mechanisms and altering the
chromatin conformation and transcription factor accessibility.
Several types of sequences associated with specific epige-
netic makeup are targets of a host of environmental factors
that can trigger transiently or permanently disturbed chromatin
architecture with altered epigenetic instructions – either at the
somatic or at the germline levels – leading to aberrant patterns
of gene expression.
For example,
(1) unique genes, e.g. the glucocorticoid receptor, or, more
likely, specific subsets of unique genes belonging to
different pathways or systems(55,56);
(2) genes present as multiple copies such as of genes coding
ribosomal RNA(57,58);
(3) whole genome epigenomic changes(59 – 61).
However, still little is known about the various replication/
DNA synthesis-dependent and -independent epigenetic
mechanisms underlying the stochastically, genetically and
environmentally triggered epigenetic changes occurring
during an individual’s lifetime. They may result from replica-
tion-dependent, replication-independent or DNA repair
events. Most of the epigenetic changes were thought to be
coupled to DNA replication. Thus, epigenetic patterns need
to be faithfully maintained during each cell cycle. In addition,
the maintenance of genome integrity involves specific repair
pathways(62). During the synthesis phase, this is achieved by
duplication of chromatin structure in tight coordination with
DNA replication. Histone synthesis and deposition onto DNAT
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by chromatin assembly factors ensures efficient coupling with
DNA synthesis(63). However, this faithful maintenance is not
always required. Changes in epigenetic patterns are observed
during the differentiation processes for several genes involved
in development, cellular growth, differentiation, apoptosis or
tissue- or sex-specific expression. DNA demethylation modu-
lates mouse leptin promoter activity and the insulin-sensitive
GLUT4(64) during the differentiation of 3T3-L1 cells (mouse
embryonic fibroblast – adipose-like cell line)(64,65).
The evidence for epigenetic systems. Recently, links have
been found between circadian rhythms and major components
of energy homoeostasis, thermogenesis and hunger–satiety,
rest–activity rhythms and the sleep–wake cycle(66,67). The
rhythmic, circadian induction of a substantial proportion of
genes, by a network of clock genes, one of which is a histone
acetyltransferase, by nuclear receptors and transcription
factors is also controlled by chromatin remodelling. The
associated circadian epigenetic patterns must be replication-
independent, transient, sensitive to environmental cues and
reversible. However, poorly adapted behaviour or lifestyle
and desynchronised cues may disturb the modulation of
gene expression. This may ultimately lead to persistence of
aberrant and unphased ‘locking’ or ‘leakage’ of gene
expression and unadapted responses of the organism in
terms of physiology, metabolism and behaviour to environ-
mental changes. Thus, epimutations accumulate over time,
increasing the ‘epigenetic burden’ potentially leading to the
onset of age- and/or environment-related diseases(68). The life-
long remodelling of our epigenomes by nutritional metabolic
and behavioural factors corresponds to the new field of ‘nutri-
tional epigenomics’.
Trans-generational effects. It is now widely accepted that
the developmental basis of adult diseases and the non-Mendelian
transmission of acquired traits cannot be attributed solely
to genetic mutations or a single aetiology(69). In addition, there
is accumulating evidence that during the periconceptual, fetal
and infant phases of life, exposure to environmental compounds
or behaviours, placental insufficiency, maternal inadequate
nutrition and metabolic disturbances can promote improper
‘epigenetic programming’, leading to susceptibility to various
disease states or lesions in the first generation and sometimes
subsequent generations, i.e. transgenerational effects. While
developmental programming may imply an altered uterine
milieu perpetuating the disease risk through the cycle of
mother-to-daughter transmission, with epigenomic alterations
at the somatic level, there are also examples of transmission
through the germline for both sexes and with sexually dimorphic
effects(70,71). There are an increasing number of animal models,
designed to mimic human conditions, that clearly involve an
epigenetic and/or gene expression-based mechanism and
these have recently been reviewed(72).
DNA methylation alterations and/or histone modifications
involve different types of sequences either at the somatic or
at the germline levels. However, very little information is pre-
sently available to evaluate the actual impact, persistence, and
dietary and therapeutic reversibility of these environmentally
triggered transgenerational effects. It remains difficult to
determine the conditions required for the persistence of trans-
generational effects over several generations, even in the
absence of the original stimulus. It also remains unclear
whether the continuation of exposure over several generations
leads to ‘locked’ epigenomic patterns. If this were the case,
permanently methylated cytosines, with their higher rate of
mutation, would give rise to genuine genetic mutations,
thereby persisting in the genome. This would have important
consequences for adaptation to new environments – coping
with the worldwide epidemic of obesity, for instance.
Epigenetic studies in human subjects. Recent studies also
suggest that part of the epigenetic component can be depen-
dent on genetic changes: there is a genetic basis for epigenetic
variability between individuals, in stochastic events, suscepti-
bility to environment/diets, to replication-dependent and
replication-independent events. The finding that DNA methyl-
ation profiles can be associated with particular alleles is of
considerable interest. Only a few studies in human subjects
have identified associations between DNA sequence and
epigenetic profiles. The present population-based approach
to common diseases relates common DNA sequence variants
to either disease status or incremental quantitative traits contri-
buting to disease. This purely genetic approach is powerful
and general, and Bjornsson et al.(73) have proposed an
approach to incorporate epigenetic variation into genetic
studies. Indeed, it could be that epigenetic variation (including
at the epiallele and epihaplotype) may be a better predictor for
risk of disease, including late onset and progressive nature of
complex diseases than sequence-based approaches alone(74,75).
Future studies in epigenetics. Depending on the nature
and intensity of the insult, the critical spatiotemporal windows
and developmental or lifelong processes involved, these epige-
netic alterations can lead to permanent changes in tissue and
organ structure and function; alternatively, some of the
gene- and/or tissue-specific changes can be reversible by
means of appropriate epigenetic tools. Given several encoura-
ging trials, prevention and therapy of age- and lifestyle-related
diseases by individualised tailoring to optimal epigenetic diets
or drugs are conceivable(76,77). However, these potential inter-
ventions will require intense efforts to unravel the complexity
of these epigenetic, genetic, stochastic and environmental
interactions and to evaluate their potential reversibility with
minimal side effects. Given the significant and increasing pro-
portion of women who are overweight and overfed when preg-
nant paying attention to the over-nourished fetus is as
important as investigating the growth retarded one(78). Improving
the environment to which an individual is exposed during
development may be as important as any other public health
effort to enhance population health worldwide(70). It is clear
that epigenetic alterations can no longer be ignored in
evaluations of the causes of obesity and its associated
disorders. There is a need for systematic large-scale epigenetic
studies on obesity, employing appropriate strategies and
techniques and appropriately chosen environmental factors
during critical spatiotemporal windows in development.
Perinatal nutrition and CVD in adults
Background to diet effects
The possible impact of perinatal nutrition (including both
in utero nutrition and lactation) on the development of CVD
in adulthood is a very complex issue, mainly because of
the very slow evolution of the disease before clinical
manifestation. The progression of fatty streaks to coronary
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atherosclerosis and then to the stenosis that will provoke
cardiac ischaemia or infarction may require 50 years. More-
over, the possible evolution of infarct (or hypertension) to
cardiac hypertrophy and/or chronic heart failure may also
require a long duration. This cardiac disease ‘continuum’
has been related to several risk factors, including cholesterol
levels, diabetes, obesity, sedentarity, coagulation, smoking,
dietary practices and vascular dysfunction. In this context, it
is difficult to evaluate the possible influence of the perinatal
environment, including maternal factors (genotype, nutrition,
disease state including dyslipidaemia, gestational diabetes
and hypertension), fetal predisposition (genotype develop-
ment) and lactation. It is obviously difficult to differentiate
these early putative risk factors from those which develop
later independently of the link from childhood to adulthood.
Epidemiological evidence of association
Hypertension. Birth triggers the transition from a low
blood pressure system to a high blood pressure system.
Intra-uterine undernutrition is known to affect later hyper-
tension both in experimental animals and in human subjects
and the mechanism has been investigated(79). Intra-uterine
undernutrition impairs nephrogenesis and glomerular hyper-
trophy. These developmental alterations induce decreased
filtration rate and a decreased plasma flow that will contrib-
ute to increased blood pressure. Besides this kidney func-
tional alteration, intra-uterine undernutrition also affects the
endothelium function. The mechanism involves a reduction
of superoxide dismutase activity, an increase in NADPH
oxidase activity and a decrease nitric oxide synthase gene
expression and activity. As a consequence, nitric oxide pro-
duction is reduced, whereas free radical oxygen is increased,
resulting in a change in relaxation of vascular smooth
muscle cells.
The quality of lactation was also shown to affect blood
pressure in human subjects. Diastolic and mean blood
pressure at the age 13–16 years were significantly lower
in children previously fed banked breast milk compared
with children fed either term or preterm infant formulas.
Moreover, the authors report than the results remained
unchanged after adjustment for present BMI, sex and Na
intake(80). However, this result was not confirmed in large-
scale epidemiological studies. The Oxford Nutrition Survey
investigated pregnant women recruited in 1942–4 to deter-
mine whether the wartime dietary rations were sufficient
to prevent the deficiencies. More than 50 years later, the
offspring were recruited to explore the possible impact of
maternal nutrition in pregnancy on CHD risk factors, includ-
ing blood pressure, but the results provided no evidence to
support the hypothesis that birth weight or undernutrition
in pregnancy affect hypertension(81). Similarly, The Boyd
Orr Cohort investigated a cohort of children born 1937–9
and their follow-up in 732 adults aged 65 years and this
reported no evidence of the influence of breast-feeding on
blood pressure(82).
Athersclerosis. The Boyd Orr Cohort, comprising 700
adults between in the years 1937 and 1939 (see above),
was recently reinvestigated. The authors report that the
breast-fed group displayed lower intima-media thickness of
carotid arteries and a lower score in carotid and femoral
plaques(82). The results remained unchanged after adjustment
for socio-economic variables (including smoking and alco-
hol), and adjustment for pathway causal factors (including
blood pressure, adiposity, cholesterol, insulin resistance and
C-reactive protein). Atherosclerosis is considered to begin
very early in life as shown in the Fate of Early Lesions in
Children Study(83). This study showed that maternal hyper-
cholesterolaemia during pregnancy induces changes in fetal
aorta that may determine the long-term susceptibility of chil-
dren to fatty-streak formation and subsequent atherosclerosis.
The human fetus displays arterial fatty streaks in utero.
Although these fatty streaks regress after birth, they redeve-
lop rapidly independently of the cholesterol status of the
child. The study reports that these fatty streaks are associated
with an increase in arterial wall thickness (aorta and caro-
tids) in child than in fetus. Investigations in animals(84)
showed similar results, the offspring of hypercholesterolaemic
mothers displaying a significantly higher atherosclerosis
lesion score at birth, at 6 months and at 12 months. Interes-
tingly, when the mothers were treated with cholestyramine
during pregnancy, the atherosclerosis lesion score in the
offspring was significantly lower at birth and at 6 months
and fully normalised at 12 months(81). However, although
several nutrients, including phytosterols, the SFA:PUFA
ratio and n-3 PUFA, affect cholesterol transport in adults,
the impact of these nutrients in early development has not
been considered so far.
Myocardium and coronaropathies. The Helsinki Birth
Cohort Study including more than 4000 men born 1934–4
reported a significant correlation between the ponderal index
at birth (term babies only), early growth and the standardised
mortality ratios for CHD(85). Low birth weight and low pond-
eral index were associated with increased CHD. After 1 year
of age, rapid gain in weight and BMI increased the risk of
CHD in those men with a low ponderal index at birth. Epide-
miological studies can be confusing. Investigations in the
‘Nurses’ Health Study’ cohort suggested that breast-feeding
may be associated with a reduction in risk of ischaemic
CVD in adulthood(86). Conversely, investigations on the
‘Caerphilly study’ cohort data provide little evidence of a
protective influence of breast-feeding on CVD risk factors,
incidence or mortality. Moreover, a possible adverse effect
of breast-feeding on CHD incidence was reported, which
may be related to the difficulties in differentiating the
lactation effects from the individual risk factors developed
after weaning(87).
In the perinatal period, the myocardium is subjected to
several key changes and some of these changes will induce
a phenotype influencing cardiac function. These could be the
key parameters in the pathology developed in later life such
as mitochondria oxidative capacity and adrenergic regulation
of cardiac function, both through membrane phospholipid
homoeostasis.
Critical developmental stage
The question is then restricted to the developmental stage
during which the specific impact of the perinatal nutrition
period on the development of CVD, independently from
the known risk factors, developed during independent life.
This may affect hypertension, atherosclerosis development
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and localisation, individual sensitivity to ischaemia and
preconditioning, occurrence and severity of infarct, develop-
ment of cardiac hypertrophy and its evolution in chronic
heart failure.
Several organ systems which can subsequently influence
cardiovascular function via programming mechanisms
have been documented in human subjects. These include
the vessels (vascular compliance and endothelial function),
the endocrine system (glucose and insulin metabolism), the
muscles (glycolysis in exercise and insulin resistance), the
kidneys (rennin–angiotensin system) and the liver (cholesterol
metabolism, fibrinogen and factor VII)(88). However, all these
investigations referred specifically to perinatal dietary
restriction and raise the issue of qualitative concern.
Moreover, the data on the heart itself are scarce and the role
of metabolic programming that may affect cardiac metabolism
and function is unclear.
Mitochondria oxidising capacity. The transition of the car-
diomyocyte energy production system from exclusive
glucose oxidation to fatty acid (FA) oxidation allows the
large increase in cardiac energy production capacity as required
by independent life. This process is based on a large increase in
mitochondria mass controlled by several key factors including
mitochondrial DNA (always from maternal origin) mainly
encoding for the electron transport chain, transcriptional
co-activator PGC-1a(89) which controls mitochondrial biogen-
esis, the development of FA oxidation pathways(90,91)and also
cardiolipin (CL) synthesis through PPAR. Feeding dam rats a
high-fat diet during pregnancy resulted in offspring which
at 6 months display a significant decrease in mitochondria
encoding mRNAs (mainly cytochrome oxidase subunits, dicar-
boxylate carrier and mitochondrial genome)(33). CL is the key
phospholipid in the function of inner mitochondrial membrane
ensuring the cohesion of the electron transport chain and
associated enzymes. At the cellular level, cardiac ischaemia
is basically a crisis of energy production associated with an
unbalanced ratio in substrate oxidation (excessive FA oxidation
and decreased glucose oxidation)(92). This unbalanced metab-
olism contributes to the rapid oxidation of CL which decreases
in mitochondrial membranes, impairing energy production(93).
The cardiac capacity to restore CL is partly controlled by the
effect of LCPUFA on PPAR, and maternal diet was reported
to influence the acyl composition of CL (and hence its sensi-
tivity to oxidation) via both FA placental transfer and breast
milk(94). However, chronic heart failure is associated to a
decreased capacity of the cardiomyocytes to produce energy
from FA resulting in a reduced capacity to face any increase
in energy demand (the term ‘metabolic regression to fetal
phenotype’ is often encountered in the literature)(91). The effi-
ciency of mitochondrial biogenesis and CL synthesis and
the basal mitochondrial mass are key factors in cardiac
pathophysiology.
Cardiac function. The perinatal period is also associated
with the transition in the neurohumoral regulation of cardiac
function to a large predominance of the b-adrenergic system.
This system involves the internalisation of the receptor
and its recycling to sarcolemma (clathrin-mediated recycling)
in which phosphatidylinositol-3-kinase plays a key role.
The use of b-blockers in the treatment of cardiac
disease including coronaropathy and chronic heart failure
outlines the importance of the basal b-adrenergic function.
The development of this pathway is based on the membrane
homoeostasis of phosphatidylinositol, the substrate of phospha-
tidylinositol-3-kinase. This enzyme is also involved in insulin
signalling by triggering the translocation of GLUT4 to the
membrane. The early development of the phosphatidyl-
inositol-3-kinase pathway may thus impact on both neuro-
humoral regulation of cardiac function and insulin control of
cardiac metabolism, since insulin contributes to myocardium
substrate balance through the regulation of AMP-activated
kinase-like leptin and adiponectin.
Experimental evidence and mechanistic understanding
Several attempts have been made, using animal models, to
investigate the cardiac consequences of in utero nutrition.
The effect of maternal undernutrition during pregnancy was
studied using sheep as a model system. Dong et al.(95) reported
a change in the expression of insulin-like growth factor
(IGF-1), IGF-1R and IGF-2R, in fetal myocardium associated
with a ventricular enlargement in fetus. Han et al.(96) reported
several alterations of gene expression and particularly the up-
regulation for several proteins that have been linked to cardiac
hypertrophy and compensatory growth in several species
including human subjects. Other authors reported in the
same model that maternal undernutrition decreased immuno-
reactive type 1 and type 2 angiotensin-II receptors (AT1 and
AT2) in the left ventricle of the fetuses without affecting
gene transcription of the angiotensin-II receptors or increased
the transcription of mRNA for vascular endothelial growth
factor, whereas immunoreactive vascular endothelial growth
factor remained unchanged. All together, these data suggest
a relationship between maternal undernutrition and later
cardiac remodelling processes. The rat is another frequently
used model. Studies have included the link between maternal
dietary isoflavones and the sensitivity to dilatation and chronic
heart failure of offspring, the influence of litter size on cardiac
neurohumoral control, the influence of maternal nutrition on
cardiomyocyte length which affects left ventricle capacity in
overload and the effect of high-fat diet in mothers on mito-
chondrial DNA expression.
The role of specific nutrients possibly involved in meta-
bolic imprinting of blood pressure and dietary fat has been
investigated. In animal experiments (rats), Khan et al.(97)
reported an increase in systolic and diastolic blood pressure
in the adult offspring of dam fed a high-SFA diet during
pregnancy. Interestingly, this increase was observed in
female offspring but not in males. Investigations on the
mechanism showed a significant alteration of endothelial
function associated with a modified arterial lipid composition,
which could result from a misbalanced SFA:PUFA ratio
during early growth(98). Such an effect of LCPUFA was
also reported in children. Forsyth et al. compared three
groups of infants fed an infant formula or the same formula
supplemented with arachidonic acid and DHA or breastfed
(also providing arachidonic acid and DHA). After weaning,
the children were allowed to return to a non-controlled diet
and re-examined 6 years later. The results showed a lower
diastolic and mean blood pressure in those children who
received LCPUFA during lactation either by breastfeeding
or by supplementation.(99) The mechanism is still unknown
but could be related with the differential effect of each
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LCPUFA on blood pressure according to hypertension
aetiology as reported in animal models.
Conclusion and future directions
In conclusion, metabolic programming of the cardiovascular
system cannot be considered yet as proven, in spite of several
promising results. The range of animal investigations does not
suggest a trend in the relationship between perinatal nutrition
and adult cardiac function, and/or protection can be con-
sidered to be confirmed. Epidemiological studies remain
unconvincing and often controversial. In addition, so far,
they cover only the domains of maternal food restriction and
breast-feeding. In between, there is a strong requirement for
mechanistic investigations to provide science-based infor-
mation on the influence of maternal diet on offspring heart
function and protection from later disease. Also, these investi-
gations will have to include the globally misbalanced dietary
habits (low protein and high fat) as well as the influence of
specific nutrients such as specific FA, glycaemic index,
amino acids, salt and minerals, sterols or phytohormones.
Role of perinatal leptin in obesity risk/incidence in adults
Background to diet effects
The incidence of obesity, defined as a BMI .30 kg/m2, is
rapidly increasing all over the world(100). The epidemic now
affects young children and accumulative evidence suggest
that, in part, the origin of the disease may be influenced by
fetal development and early life. Nutritional and hormonal
status during pregnancy and early life could interfere irrever-
sibly on the development of the organs involved in the
control of food intake and metabolism and particularly the
hypothalamic structures responsible for the establishment of
the ingestive behaviour and regulation of energy expenditure.
The mechanisms responsible for this developmental
programming remain poorly documented. While obesity is
a multi-factorial problem and is affected by several factors,
recent research indicates that the adipokine leptin plays a
critical role in this programming(101).
Leptin sources and biological functions. Leptin is pro-
duced essentially by the adipose tissue and its plasma levels
reflect the fat reserves. There are also several extra adipose
sources of leptin. The placenta in human subjects (but not in
all species) produces leptin and constitutes an appreciable
source of leptin for the fetus during pregnancy(102). The mam-
mary gland is also able to produce leptin, particularly during
the early phase of lactation(103). In addition, the mammary
gland is involved in the transport of leptin from the mother
to the milk, which is an additional source of leptin for the
newborn(104). The immature gastrointestinal tract may allow
leptin to enter the circulation, but it is likely that leptin may
have considerable effects locally and play a role in the matu-
ration of the epithelial lining of the gut. There are leptin recep-
tors present in the gastrointestinal tract, which suggests
a localised function. Although initially there may be leptin
leakage to the circulation because of gastrointestinal immatur-
ity, access of leptin to the circulation may be limited.
Leptin is involved in an extensive number of biological
functions and several isoforms of the receptor have been
identified in different organs. The best-known effects are
those exerted at the hypothalamic level where the long form
of the leptin receptor is predominantly expressed and exerts
a pivotal role in the regulation of food intake. In peripheral
organs, the short form of the leptin receptor is the dominant
form expressed and its biological effects include cell prolifer-
ation and cell differentiation in adipose tissue, pancreas, liver,
kidney, arteries and immune cells.
Leptin and regulation of food intake. At the hypothalamic
level, after crossing the brain–blood barrier, leptin interacts
with a complex neuronal network integrating a wide range
of nervous, nutritional and hormonal signals. Leptin interacts
primarily with the arcuates nucleus, where it inhibits the
activity of neurons expressing orexigenic peptides (neuropeptide
Y and Agouti-related protein) connected to the lateralhypotha-
lamic nucleus which is recognised as a major controlling
factor in hunger. Leptin also stimulates the activity of anorexi-
genic neurons expressing pro-opiomelanocortin connected to
ventromedial nucleus recognised as the centre of satiety.
The different hypothalamic nuclei are interconnected via a
complex neuronal network with paraventricular and
dorsomedial nuclei and the integration of all these stimuli
determines the food intake behaviour(105).
Epidemiological evidence for association
There is little epidemiological evidence for an association
between circulating leptin and obesity. To briefly summarise,
there is a rare leptin gene mutation that causes obesity in early
childhood. Small-for-gestational age and preterms have
lowered leptin levels. Family history of obesity has been
correlated with high umbilical cord levels of leptin.
Critical developmental stage
Leptin stimulation results in a decrease in food intake, and it
was initially hoped that exogenous leptin therapy might induce
satiety and weight loss in the obese human. Unfortunately, it
has been found that obesity is often associated with a ‘leptin
resistance’, which is progressively established during inges-
tion of a hypercaloric diet and associated with an increase
of serum leptin levels. The mechanisms underlying leptin
resistance remain a matter of debate, but the two hypotheses
that have received the most attention are a failure of circulat-
ing leptin to reach its target cells in the brain or a blockage of
leptin signalling by activation of suppressor of signalling
(SOCS3) or specific phosphatases (PTP1b). An alternative
hypothesis suggests that leptin resistance may in fact be pro-
grammed during fetal and neonatal life and may be the
result of an altered development of neuronal circuitry involved
in food intake regulation.
The neuronal network is established during hypothalamic
development occurring postnatally in rodents. In the mouse,
dense neuronal fibre originating from the arcuate nucleus
and reaching lateral and dorsomedian hypothalamus and para-
ventricular nucleus are progressively established between days
6 and 16. The development of this neuronal network occurs at
the same period as a dramatic increase in leptin level occurs
in the blood, the suggested origin of which is adipose tissue.
This change in leptin levels is not related to food intake regu-
lation since body weight of the animals rapidly increases
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at this period. Bouret, in the group of Simerly(106,107), clearly
demonstrated that leptin at this period exerts a potent neuro-
trophic action. These authors have observed that ob/ob mice,
genetically deficient in leptin, have an altered hypothalamic
development characterised by a dramatic decrease in neuronal
fibre density in the hypothalamic structures. Secondly, they
elegantly demonstrated that leptin administration to these
animals during the early postnatal period restored neuronal
organisation of hypothalamic circuits in term of fibre density
in the paraventricular nucleus. Finally, hypothalamic connec-
tions in the diet-induced obese rat model were shown to be
permanently disrupted(108).
Experimental evidence and mechanistic understanding
Several animal models have clearly shown that either severe
undernutrition during pregnancy or placental deficiency,
induce intra-uterine growth retardation (IUGR) leading to
low birth weight which is associated with low leptin levels.
It is also well established that the IUGR newborn show an
increased susceptibility to develop obesity and metabolic syn-
drome when submitted to high-caloric diet during later life.
One possible explanation is that leptin deficiency in IUGR
causes improper programming. Supporting this hypothesis, it
has been recently demonstrated(109) that neonatal leptin treat-
ment of IUGR pups reverses developmental programming
induced by mother’s severe undernutrition and restores
normal adult phenotype. To extend these findings to normal
birth weight animals and taking advantage of the recent devel-
opment of specific leptin antagonist(110), we have recently ana-
lysed the consequences of the blockage of the postnatal leptin
surge in newborn rats(111). Leptin mutants (L39A/D40A/
F41A/I42) which bind to the leptin receptor with an affinity
identical to wild-type leptin, but are completely devoid of
agonistic activity, have been administered during early post-
natal days 2–13. Three months later, the animals were given
a leptin challenge and these animals injected with the leptin
antagonist early in life were leptin resistant. When a high-
energy diet was given to these animals, they showed a
higher susceptibility and a greater increase in body weight
than control animals. At 8 months, the animals presented a
higher adiposity associated with hyperleptinaemia. These
data demonstrate that perinatal leptin in a normal situation
plays a crucial role in the determination of the capacity of
the animal to respond to leptin later in life and to protect
the newborn against the adverse effect of hypercaloric diet.
Several studies have documented the evolution of leptin
levels during pregnancy in normal and IUGR babies. It has
been shown that leptin levels increased during late fetal life,
and at birth, leptin levels are lower in IUGR babies than in
normal weight newborn(112). The chronology in the develop-
ment of the different organs varies between animal species.
In contrast to the rodent, the major part of neuronal develop-
ment occurs before birth in the human(113). However, it is
evident that a relative neuronal plasticity remains after
birth and this could be even more so in the case of IUGR,
where an impairment in the development of several organs
(particularly the kidney) is generally observed. As we
mentioned earlier, the mammary gland is able to produce
leptin and also to transfer leptin from mother’s blood to
milk. An interesting possibility is to consider that leptin
absorbed by the newborn via the milk may be an important
factor, which participates in the final maturation of different
organs such as the intestine and also hypothalamic structures
involved in food intake regulation. Several studies seem to
support this hypothesis. Indeed, it has been reported that
breast-fed infants have higher serum leptin levels than
formula-fed infants(114) and that breast-fed infants may show
an decreased risk of developing obesity(115).
Experimentally, it has been demonstrated that the intake of
physiological doses of leptin during lactation in rats prevents
obesity in later life(116). All these facts support the idea that
milk leptin may play a favourable role in developmental pro-
gramming and constitute a credible candidate to explain, at
least partially, the protective effect of breast-feeding against
obesity. This is an interesting subject for future investigations.
In mice, the leptin responsible for the hypothalamic develop-
ment of the hypothalamic food intake circuitry is thought to be
of adipose tissue origin of the newborn despite its very small
quantity.
Conclusions and future directions
All the data summarised in this paper suggest that leptin
constitutes a key hormonal player during the perinatal period
in the prevention of unfavourable developmental programming.
Additional basic research is necessary to establish the bio-
logical mechanisms involved. In addition to classical rodent
models, animal models including sheep or pigs may be
useful as models of the human situation. Indeed, as in
human subjects, the major part of neuronal hypothalamic
development occurs before birth in these two species, although
it should be noted that, in the human, major synaptic prolifer-
ation occurs after birth. Epigenetic modulations are probably
involved in this developmental process and the genes impli-
cated remain to be established.
Different strategies could be envisaged to optimise the
effects of leptin during developmental programming. Parti-
cular attention must be given to nutrition during pregnancy.
Development of well-adapted diets associated with optimised
maternal leptin levels would be beneficial.
During the postnatal period, several months of breast-
feeding must be encouraged, particularly in IUGR babies.
Opportunities for research on the optimisation of the postnatal
diet during the critical developmental stage could potentially
focus on leptin and its addition to infant formula, for instance.
Perinatal nutrition and type 1 diabetes in adults
Background to diet effects
Type 1 diabetes (T1D), a chronic inflammatory disease caused
by a selective destruction of the insulin-producing b-cells of
the pancreas, is one of the most common and serious chronic
diseases in children(117,118). The incidence is increasing by 3 %
per year, particularly in young children and in developed
countries(118).
T1D is preceded by a pre-clinical phase characterised
by autoimmunity against pancreatic islets(119). A genetic
susceptibility for developing islet autoimmunity and T1D is
well documented and an environmental influence is
assumed(120).
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Epidemiological evidence for association
Over the last 15 years, several groups have initiated prospec-
tive studies from birth investigating the development of islet
autoimmunity and diabetes(121 – 124). These studies provide an
opportunity to investigate the factors that are associated with
the development of islet autoimmunity and progression to
T1D. Findings from these studies have significantly contri-
buted to our present understanding of the pathogenesis of
childhood diabetes. However, the exact aetiology and patho-
genesis of T1D are still unknown.
Genetic factors influencing the development of islet auto-
immunity and type 1 diabetes. Children with a first-degree
relative with T1D have a more than tenfold higher risk to
develop T1D, further increasing if both parents were affected.
Genetic variability in the human leucocyte antigen region
explains approximately 50 % of the familiar clustering(125,126);
other genes have also been identified as providing more
modest contributions to risk(126,127). The concordance of
T1D between monozygotic twins is up to 50 %, whereas
between dizygotic twins, it is only 10 %(128). Although such
differences in the concordance rates between identical and
non-identical twins clearly underline the impact of genes on
the development of T1D, they also show that genetic suscep-
tibility alone cannot be the ultimate cause for the disease and
that environmental factors seem to modify the risk for islet
autoimmunity and T1D.
Environmental factors influencing the development of islet
autoimmunity. Prospective studies from birth have demon-
strated that islet autoimmunity occurs very early in life.
Around 4 % of offspring of parents with T1D in the BABY-
DIAB (genetic risk of developing T1D) study and about 6 %
of genetically at-risk infants from the general population in
the Finnish Diabetes Prediction and Prevention study have
developed islet autoantibodies by age 2(129,130). Children
who develop autoantibodies within the first 2 years of life
are those who most often develop multiple islet autoantibodies
and progress to T1D in childhood(129). These findings impli-
cate environmental factors that are encountered before age 2
may be important for the development of islet autoimmunity.
Candidate environmental factors that are suspected to influ-
ence risk for islet autoimmunity in genetically susceptible
individuals are dietary factors and factors associated with
maternal diabetes.
Critical developmental stage
There are several dietary factors that are proposed to be
associated with the development of islet autoimmunity and
T1D but most of the research done in this field led to contro-
versial results. There are only few prospective case–control,
cohort and human-intervention studies that can be used for
hypothesis testing. However, dietary factors that have already
been related to the development of islet autoimmunity and
T1D were examined in these following prospective studies
(Fig. 3). Recently, weight gain in early life was proposed
to predict the risk of islet autoimmunity in children with a
first-degree relative with T1D(131).
It has been suggested by some investigators that
breast-feeding may protect against T1D(132), whereas early
introduction of supplementary milk feeding may promote
the development of islet autoantibodies and T1D(133).
Four prospective studies in at-risk neonates have not demon-
strated an increased risk for developing islet autoantibodies
in children who were not breast-fed and received cow’s milk
(CM) proteins early in life(134 – 137). However, recent results
suggest that an enhanced humoral immune response to various
CM proteins in infancy is seen in a subgroup of those
children who later progress to T1D. The authors imply that
a dysregulated immune response to oral antigens may be an
early event in the pathogenesis of T1D(138).
Another candidate factor is the early introduction of solid
food in an infant’s diet. In two recent prospective studies, it
was suggested that risk of development of islet autoimmunity
is increased in children who were exposed to cereal proteins,
and particularly gluten, early in life(139,140). The BABYDIAB
study looked at the impact of food supplementation during the
first 3 months of life on the development of islet autoimmunity
in offspring of parents with T1D. Children who received gluten-
containing supplements during the first 3 months of life had a
significantly higher risk of developing islet autoimmunity com-
pared with children who received nongluten-containing solid
food, CM-based supplements or who were breast-fed only.
The Finnish Diabetes Prediction and Prevention study showed
that the introduction of fruits and berries before 4 months of
life was associated with a significantly higher risk of developing
islet autoimmunity compared with children who received solid
food supplements later in life(137).
Dietary factors that have been proposed to protect
from islet autoimmunity are vitamin D and n-3 fatty acids.
0·12 0·25 0·5 0 2 4 8
Fruits and berries < 3·5 months, DIPP 
Cereal < 3 months; DAISY(142)
Gluten < 3 months; BABYDIAB 
Hazards ratio
Exclusive breastfeeding 0·1–3 months
BABYDIAB
Cow‘s milk < 3 months, DIPP
Cow‘s milk < 1 months, DAISY
Cow‘s milk < 3 months, BABYDIAB
Maternal Vitamin D intake
Fig. 3. Studies of the hazards ratios for risk of T1D
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The prospective Dietary Autoimmunity Study in the Young
showed that dietary maternal intake of vitamin D was signifi-
cantly associated with a decreased risk of islet autoimmunity
appearance in offspring who were at increased risk for T1D
(including a dose–response effect!). Neither vitamin D
intake via supplements nor the n-3 and n-6 fatty acids intake
via supplements during pregnancy was associated with the
appearance of islet autoimmunity in offspring(141,142).
Experimental evidence and mechanistic understanding
There are several ongoing dietary intervention trials in
newborns at high risk for T1D:
Trial to reduce type 1 diabetes in the genetically at risk
(TRIGR). To study the impact of CM proteins in an infant’s
diet on the development of islet autoimmunity and T1D, an
interventional trial, the trial to reduce T1D in the genetically
at risk, is presently ongoing in children with increased genetic
risk and who have a first-degree relative with T1D(143). The
trial has a double-blind, prospective, placebo-controlled inter-
vention protocol, comparing casein hydrolysate with a con-
ventional CM-based formula. The ‘trial to reduce T1D in
the genetically at risk’ is an international multicentre study
with seventy-eight clinical centres in fifteen countries. The
recruitment of families for the trial to reduce T1D in the
genetically at risk study was completed at the end of 2006.
Altogether, 2162 children were included in the intervention
study and will be followed up until the age of 10 years.
BABYDIET. The German-wide BABYDIET study, an
interventional trial, has been initiated to investigate whether
delaying dietary gluten introduction influences the develop-
ment of islet autoimmunity in newborns at genetically high
risk for T1D and with a first-degree relative with T1D(144).
Children participating in BABYDIET are randomised to one
of two dietary intervention groups that introduce gluten-
containing cereals either at age 6 months, as recommended
by the German National Committee for the Promotion of
Breastfeeding, or at age 12 months (intervention group). The
recruitment of children was finished in 2006 and altogether
150 children have been enrolled and will be followed up until
the age of 10 years. The first results are expected for 2010.
The nutritional intervention to prevent type 1 diabetes pilot
study. The nutritional intervention to prevent type 1 diabetes
study has been initiated to investigate whether DHA sup-
plementation during pregnancy and early childhood will pre-
vent development of islet autoimmunity in children at high
genetic risk for T1D and with a family history of T1D. Eli-
gible participants (pregnant women or infants) will be ran-
domised to one of the two study groups: a DHA group
(intervention) or a control study group substance (placebo).
During pregnancy and while breast-feeding, infants will
receive the study substance indirectly through their mother
(either via the placenta or via the breast milk). Infants who
are either partially or exclusively formula fed will receive
DHA more directly through the study formula. By 6–12
months of age, all the infants will get the supplement added
to solid foods. Recruitment of families for the nutritional inter-
vention to prevent study is still ongoing.
Maternal transfer of islet autoantibodies. The influence of
maternally transmitted islet autoantibodies on the development
of islet autoimmunity and T1D has been examined both in
animal models and human subjects. In the non-obese diabetic
(NOD) mouse, removal of maternally transmitted Ig prevented
spontaneous diabetes in offspring mice, suggesting that
maternal antibodies present during gestation including islet
autoantibodies could be important factors in the pathogenesis
of b-cell destruction(145). Further studies in mice looking
specifically at whether maternal insulin antibodies influence
diabetes development reported controversial findings(146,147).
In the BABYDIAB study, 86 % of offspring from mothers
with T1D have antibodies to exogenously administered insulin
at birth and 66 % of offspring have antibodies to glutamic acid
decarboxylase and/or islet antigens-2A at birth. The presence
or absence of maternal insulin antibodies did not affect the
risk of developing diabetes-associated autoantibodies and
T1D in the child, but offspring with antibodies to glutamic
acid decarboxylase and/or islet antigens-2A at birth had a sig-
nificantly lower diabetes risk than offspring who were auto-
antibody-negative at birth(148). Therefore, and in contrast to
the data from animal studies, these findings in human subjects
do not support the hypothesis that fetal exposure to islet auto-
antibodies increases the diabetes risk, but rather suggest that
fetal exposure to antibodies to glutamic acid decarboxylase
and/or islet antigens-2A may protect from future endogenous
islet autoimmunity and T1D. Consistent with this observation
is the overall decreased risk to develop islet autoimmunity and
diabetes in offspring of mothers with T1D compared with that
of offspring of fathers with T1D and nondiabetic
mothers(149,150).
There is evidence that early exposure to environmental
factors during pregnancy and/or early infancy influences the
development of islet autoimmunity and T1D. However, the
etiologic mechanisms that trigger autoimmunity and promote
progression to disease are largely unknown. One major
problem is that there is no access to the autoreactive T-cells
within the pancreas that are responsible for the disease.
Thus, we are not able to quantify and characterise these cells.
Advances in these areas are necessary if we want to fully
understand the autoimmune pathogenesis of T1D. An inter-
national study (The Environmental Determinants of Diabetes
in the Young), sponsored by the National Institutes of
Health, is ongoing to address the early pathogenic mechanisms
operating in islet autoimmunity(151). These are long but
necessary studies that we hope will provide us with the knowl-
edge of the environmental factors that affect the disease
process.
Conclusions and future directions
The link between early dietary exposure and the onset of T1D
in susceptible individuals remains unproven. However, most
of the investigators in the area point to the increasing inci-
dence of T1D as evidence that the most likely causative
factor is environmental rather than genetic. In most of the
cases, the results of studies that pinpoint a link between
early diet and the later onset of T1D have been controversial
and there are a few prospective case–control, cohort and
human intervention studies that can be used for hypothesis
testing. The conflicting evidence may, in part, be explained
by the variation in the types of genetic predisposition and in
the variable populations that have been used in studies.
However, the major factor that prevents meaningful studies
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being carried out are the availability of biomarkers that allow
researchers to detect the effects of the environment on autoim-
munity and the likelihood of progression to the disease. It is
the development of such environmentally responsive, pre-
clinical biomarkers that will enable both mechanistic studies
and improved prevention strategies to be developed. Many
of the clinical advances in the treatment of T1D rely on
post hoc interventions including islet transplantation,
immune modulation and stem-cell therapy. The possibility
of attempting to prevent the triggering of islet cell autodes-
truction or of minimising its effects until suitable therapy
can be developed may act as a very useful adjunct to clinical
intervention. It may also assist in preventing the onset of a
second cycle of islet cell destruction after treatment.
Perinatal nutrition and neurodevelopment
Background to diet effects
Neuroanatomical and neurophysiological studies show that
brain development occurs most rapidly during fetal develop-
ment and in infancy. While family influences and the external
environment undoubtedly play key roles in the child’s cogni-
tive development, there is evidence that there is a certain
degree of stability in a childs’ cognition which tracks from a
very early age(152). This suggests that early exposures possibly
experienced in utero and postnatally may be involved in
programming the brain and play a role in determining the
cognitive ability.
Suboptimal cognitive ability is of considerable public health
interest, because this leads to low educational attainment and
these individuals tend to follow a trajectory of low socio-econ-
omic position, which is associated with fewer life chances and
poorer adult health. In addition, both markers of restricted
fetal growth and measures of cognition have been consistently
associated with shorter life expectancy(153) and increased
prevalence of psychiatric outcomes such as depression(154),
schizophrenia(154 – 156) and suicide(157) as well as with adult
chronic disease such as heart disease(158). A recent Scottish
cohort study showed a 36 % increased risk of all-cause mor-
tality per standard deviation decrease (15 points) in childhood
intelligence quotient (IQ)(159).
Epidemiological evidence for association
Evidence that cognitive ability may at least partly be deter-
mined early in life and may be related to nutrition comes
from consistent associations between measures of fetal and
infant growth and neurodevelopment, with low birth weight
infants experiencing delays in reaching motor milestones
and tending to have lower IQ(160,161). In the ALSPAC, a popu-
lation-based birth cohort of more than 14 000 children from
the South West of England, who have been followed up for
18 years, birth length was associated with a decrease in the
odds of having behavioural problems at 18 months of
age(162). A recent study suggested that, in adolescents assigned
either a standard or a high-nutrient diet in the postnatal weeks
after term birth, the high-nutrient group had significantly
higher verbal IQ and caudate volume (as measured by mag-
netic resonance imaging). However, it should be noted that
caudate volume correlated significantly with verbal IQ in the
standard nutrient group only. The effect observed was selec-
tive to males only(163).
Specific nutrients. With regard to which specific nutrients
influence cognitive ability and behaviour, research has estab-
lished that n-3 fatty acids, especially DHA which is found
in abundance in the nervous system, are critical for infant
growth and neurodevelopment. However, what is not clear is
the effect of low levels of these nutrients on cognitive func-
tion. In ALSPAC, low seafood intake (known to contain
high levels of n-3 fatty acids) by the mother during pregnancy
was associated with an increased risk of suboptimal verbal IQ,
prosocial behaviour, fine motor skills, communication skills
and social development scores(164). Furthermore, Rogers
et al.(165) have shown that the frequency of IUGR in
ALSPAC children decreased with increasing maternal fish
intake – the OR of IUGR in those eating no fish was 1·85
(95 % CI 1·44, 2·38) compared with those in the highest fish
intake group. Higher maternal intake of oily fish in
ALSPAC has also been shown to be related to the offsprings’
visual development(166). Many other nutrients and micronutri-
ents aside from n-3 fatty acids have been implicated in brain
development and cognition. Iodine is an essential component
of at least two thyroid hormones necessary for neurodevelop-
ment, and iodine deficiency during pregnancy leads to fetal
hyperthyroidism and irreversible neurological and cognitive
deficits manifest as cretinism(167). However, this may just be
the tip of the iceberg, while most studies have looked at the
effect of iodine supplements on cognition in socially deprived
areas with low levels of iodine intake; a study carried out in
1221 school children in Spain, with iodine levels in the
normal range, found that IQ was related to iodine
intake(168). A further study of 227 pregnant women in the
North East of England found that approximately 40 % had
borderline iodine deficiency(169). Another micronutrient that
might influence cognition is Fe. Fe deficiency is the most
common nutritional deficiency worldwide. A lack of sufficient
Fe intake may significantly delay the development of the
central nervous system because of alterations in morphology,
neurochemistry and bioenergetics(170). Several observational
studies have found that children who experience anaemia
early in life continue along a trajectory of poor educational
performance even after the anaemia had been treated. Other
micronutrients which may be important in fetal brain develop-
ment are B-vitamins, including folate(171), choline(172), Zn(173),
vitamin D(174) and cholesterol(175).
Critical developmental stage
Prenatal environment. A substantial body of work from
animal models has demonstrated that imbalances in maternal
nutrition during pregnancy can adversely affect normal fetal
growth and neurodevelopment(176,177). Indeed, aside from
chronic exposure to tobacco smoke and alcohol, nutrition is
probably the single greatest environmental influence both on
the fetus and on the neonate, and plays a necessary role in
the maturation and functional development of the central
nervous system(178). Inadequate nutrient availability during
gestation may be related to psychiatric disease, behavioural
problems, neurodevelopmental diseases, such as autism, and
general cognition. In the human subjects, individuals exposed
to famine in utero have increased risks of schizophrenia,
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showing long-term consequences of prenatal diet on the
brain(179,180). Season of birth has also been shown to be associ-
ated with childhood IQ(181), and nutrient availability could be
responsible for this association. Nutrients found to be lacking
in the mothers’ diet could, if shown to be related to brain
development, be modified to prevent disease and ensure that
the child’s cognitive ability is not impaired.
Postnatal environment. The strongest evidence for the
effect of diet postnatally supports the developmental role of
PUFA. Observational data from, for example, the Inuit in
arctic Quebec(182) show beneficial effects on development in
general. This has also been supported by clinical studies on
pre- and full-term infants(183) and long-term studies on the
effects of n-3 supplementation on visual and cognitive devel-
opment throughout childhood(184).
Experimental evidence and mechanistic understanding
Developmental endpoints: intelligence quotient. A key
problem is that observational studies of nutrition and IQ are
subject to confounding by other lifestyle factors, which
co-segregate with diet. This was highlighted in a recent
large prospective cohort study which examined the association
between breast-feeding and IQ; the authors found that before
adjustment, breast-feeding was associated with an increase
of about 4 IQ points, but adjustment for maternal intelligence
accounted for most of this effect and when fully adjusted for a
range of relevant confounders, the association disappeared(49).
Measurement of diet is also problematic and often inaccurate
due to wide exposure categories, misreporting of intake and
recall bias(184). Large, well-conducted randomised control
trials (RCT) are not subject to confounding and bias and a
review of RCT of infants supplemented with n-3 fatty acids
v. unsupplemented infants showed a positive effect on visual
development, although evidence for neurodevelopment is
inconsistent(185). However, most of these studies looked at
infants’ diet postnatally and not in utero. One small RCT of
mothers’ diet during pregnancy found that children who
were born to mothers who had taken cod liver oil (n 48),
which is high is n-3 fatty acids, scored higher on the Mental
Processing Composite of the Kaufman Assessment Battery
for Children at 4 years of age compared with children
whose mothers had taken maize oil which is high in n-6
fatty acids (n 36)(186). A study of Fe supplementation during
pregnancy showed no effect on IQ at age 4, but supplemen-
tation only began at 20 weeks of pregnancy and a large
proportion of children were lost to follow-up (30 %)(187).
Further trial evidence is needed, but such trials would have
to recruit women before becoming pregnant in order to capture
early gestation. An alternative study design would be to use a
Mendelian randomisation approach(188,189). This could use the
existing resources from large cohort studies to produce results
more quickly and economically than an RCT and to identify
more promising targets for RCT.
Developmental endpoints: others. Another factor that may
also be relevant here in relation to cognitive, behavioural and
eye development is the development of generalised movement
during the first 6 months of life. This may provide a less con-
founded approach to map the formation of neural connections
as a marker of brain development that can be determined rela-
tively early in life, predicts neurodevelopmental outcome at
4 years and is influenced by LCPUFA status pre and postnatally
in healthy term infants(190,191).
Mendelian randomisation as a tool for overcoming
confounding. Associations between genetic polymorphisms
and phenotype are not generally subject to the problems of
reverse causality, measurement error and confounding by life-
style factors which occur in epidemiological studies(188,189,192).
The use of genes as surrogates for measuring exposures in
epidemiology has been termed Mendelian randomisation and
is gaining recognition as an important research tool.
Genetic polymorphisms, which affect exposure to specific
nutrients by influencing the diet, altering the metabolism or
cell receptor function can be used to determine whether the
related nutrients are important and to elucidate the important
biological pathways. One example is the 5,10-methylenetetra-
hydrofolatereductase enzyme which controls a rate-limiting
step in the folate metabolic pathway. The T allele at the
C677T polymorphic site of this gene produces a thermolabile
variant, which has a reduced catalytic capacity and results in
less folate being available. This common genetic variant
mimics the effect of low levels of folate in the diet, and
associations have been found between this polymorphism in
mothers and neural tubes defects(193), which are known to
be caused by low levels of folate in the diet during pregnancy.
Further exploitation of this concept could highlight the extent
to which components of the mothers’ diet influence neuro-
development of the child.
Conclusions and future directions
There is substantial evidence, mainly from animal studies and
observational data and associations from cohort studies, that
the early environment and diet play a key role in neuro-
development. In the prenatal and early neonatal period, the
greatest environmental influence on neurodevelopment is
most likely nutrition and most beneficially from breast milk.
Dietary influences on cognitive development during the later
postnatal period are more difficult to assess from observational
studies, since such effects are subject to many confounders.
Among several micronutrients studied, DHA has shown
to be critical for infant growth and neurodevelopment.
Sub-optimal supply of other nutrients, e.g. iodine and Fe, to
fetuses and neonates might affect a range of later physiologi-
cal outcomes and, in particular, neurodevelopment(166,169).
The influence of specific nutrients, in early life, on visual
development has been extensively examined. Large well-
conducted RCT have demonstrated a positive effect of n-3
fatty acids (i.e. DHA) supplementation on visual development
in infants; however, for preterm infants, data are scarce, and
the evidence is less strong. A recent Cochrane review(194)
suggested that early intervention programmes for preterm
infants appear to have a positive effect on cognitive outcomes
in the short-to-medium term; however, further studies were
recommended(190).
The use of validated early read-outs of cognitive, beha-
vioural and visual development and the responsiveness of
these to specific dietary interventions remain very relevant.
General movement development during the first 6 months of
life could be an important marker through which optimal
neurodevelopment can be established(189,190).
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Finally, Mendelian randomisation is gaining more recog-
nition as being an important research tool by which existing
resources from large cohort studies can be used. Genetic poly-
morphisms could be helpful to determine whether particular
nutrients are potentially important and functional in the neuro-
development of the child.
Perinatal nutrition and the atopic syndrome
Background to diet effects
The atopic syndrome manifests at barrier organs of the body to
the environment. Therefore, clinical conditions on the skin
(prototypic disease atopic eczema), the respiratory tract (allergic
rhino-conjunctivitis and bronchial asthma) and at the
mucosal site of the gastrointestinal tract (food allergies) play
a major role. Despite many differences in the pathogenesis
of these different diseases, there is a distinct pattern of
common immuno-dysregulation(195 – 197). This comprises the
development of chronic inflammatory disease starting out
with a polarisation of T-cell effector responses towards a
T-helper cell-2 phenotype. This T-helper cell-2 response
controls many of the downstream effector mechanisms of
allergic disease, including IgE antibody production, tissue
and blood eosinophilia, mast cell activation and more.
Epidemiological evidence for association
Incidence and prevalence of atopic disease are still and
constantly on the rise. Particularly, in Westernised countries,
about one in three children are suffering from one type or
another or a combination of the above-mentioned clinical
phenotypes. This phenomenon clearly indicates that environ-
mental factors play a decisive role in increasing the immuno-
logical susceptibility for the development of this
immunological dysregulation(198,199). Despite all advances in
the development of anti-inflammatory medication, there is
still no primary prevention available. Furthermore, the natural
cause and chronology of the disease, as exemplified by airway
remodelling in asthmatic patients, cannot be prevented or
disrupted with present therapy. These aspects indicate the
need for better therapy and preventive measures.
Critical developmental stage
Atopic children are born in a healthy state. The earliest clini-
cal manifestation of the atopic syndrome manifests not before
the first few months in life and are primarily located at the
skin (atopic eczema) and the gut (food allergy). However,
priming of adaptive immune responses occurs prenatally.
It is now well established, for example, that antigen-specific
T-cell of fetal origin is present in cord blood(200,201). This
seems to be a physiological mechanism since virtually all
newborns carry these antigen-specific immune responses.
They are the result of intra-uterine antigen exposure and
priming.
In the development of the immuno-pathogenesis of chronic
inflammatory conditions including allergies and autoimmu-
nity, the adaptive immune system plays a very prominent
role. There are subtle differences between species in terms
of the development of T- and B-cell responses within the
prenatal environment. For example, in the human subjects,
mature single CD4 or CD8 positive T-cells are readily detect-
able at about 17–20 weeks of gestation. As a consequence,
antigens which pass the placental barrier can be presented to
such mature and immature T-cells, leading to the development
of specific T-cell immune responses. However, in mice, a
species widely used for immunological research, such naı¨ve
mature T-cells, are present only 1–2 d before birth. Therefore,
development of the antigen-specific T-cell repertoire mainly
occurs under postnatal conditions in mice. Another example
is the passage of maternal antibodies via the placental barrier.
This is an active mechanism, at least partially relating to the
expression of a unique type of Fcg-receptors – namely
FcgRn which bind, uptake and release maternal antibodies
to the fetal site(202,203). The mechanism of pre and postnatal
transfer varies for different Ig isotypes(204,205). Again, there
are distinct species differences which must be considered if
experimental studies are designed to further explore the
immuno-regulatory mechanism at this time point.
However, there is no doubt that early programming contrib-
utes to a large extent for the development of a normal state of
immunological responses. This normal state is characterised
by the development of clinical tolerance against self-antigens
as well as harmless environmental antigens. This level of
clinical tolerance depends on T-cells, is antigen specific and
must be acquired and maintained throughout life(197,206,207).
Any interruption or disturbance of this physiological process
will eventually lead to the development of disease. Concern-
ing self-antigens, autoimmunity will occur; in the case of
harmless environmental antigens, allergic and atopic disease
will develop.
Experimental evidence and mechanistic understanding
Clinical endpoints can be considered as one important set of
biomarkers and are useful to distinguish sub-phenotypes
such as airway inflammation, airway hyperresponsiveness,
development of IgE antibody profiles. Furthermore, clinical
scores (SCORAD, the clinical scoring system for atopic
dermatitis) have been established and shown to be useful in
observational as well as interventional studies. Another set
of biomarkers are immunological endpoints. They include
phenotypes and markers of the innate as well as adaptive
immune system. However, particular care must be taken in
terms of quality control and establishment of age- and sex-
specific normal ranges. An important aspect in this regard is
the assurance of inter-laboratory and inter-centre-related
quality control programmes.
Nutritional components and immune functions. There is
abundant experimental as well as epidemiological evidence
that many nutritional components are able to interfere directly
or indirectly with certain immune functions. Prominent
examples are the consumption of fish, fish oil and margarine
containing more or less well-defined levels of n-3/n-6 fatty
acids(208). One important mode of action is via interference
with the formation of phospholipids which particularly play
an important role in the formation of arachidonic acid and
its metabolites, including PG and leukotrienes which trigger
and control certain inflammatory actions. Furthermore, obesity
is to a certain degree linked to leptin levels, and, in turn, leptin
itself has effects on immune functions(209,210). The same has
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been shown for vitamin D(211). Another example for immune
functions, particularly in the field of inflammation, is the bal-
ance of oxidative and anti-oxidative capacities(212). Again, this
is influenced to some degree by nutritional factors, including
vitamins and others.
Exposure to microbes or microbial components has also
strong immuno-modulatory capacities. A prominent example
in this area is the consumption of lactobacilli like
Lactobacillus rhamnosus GG. Although the clinical benefits
of prenatal and early postnatal Lactobacillus rhamnosus GG
consumption are limited(213,214), this approach clearly indi-
cates that using microbes or microbial components opens an
avenue for further exploration. This is also highlighted by a
number of experimental studies indicating strong in vitro or
in vivo (animal model systems) effects on the development
of innate and adaptive immune responses(197). In addition,
prebiotics that fuel the intestinal microflora can also affect
the development of the immune system(215).
Although we have gained great insights into underlying
mechanisms of nutritional and microbial immuno-modulation,
particularly at early time points, we are still some way from
fully understanding the effects of such interference in detail.
However, such understanding is necessary to fully apply this
intriguing concept to allergy prevention in human subjects.
Therefore, suitable model systems must be developed for
further exploration into the mechanistic fundamentals of this
approach. In this regard, we have made some progress recently
by designing murine models for various allergic phenotypes
including acute and chronic experimental asthma with the
development of airway remodelling(216). These disease-related
models emulate more closely the real situation in patients
compared with the previous ones.
Conclusion and future directions
Development of prevention and improved intervention strat-
egies is the major goal in the area of allergy and asthma
research. The intriguing advantage of using nutritional and
microbial components is the ease of safe application, particu-
larly if applied during pregnancy, as clinical effectiveness
must be paired with safety. Furthermore, the benefit of this
intervention/prevention must be long lasting and causes no
impairment of other types of immune responses. To develop
a nutritional solution, which fulfils all of these criteria,
is a major research challenge and to reach this aim, different
avenues need to be explored. One approach is the molecular
analysis of nutritional factors, which are associated with a
reduced risk for the development of allergic disease. Another
level of investigation is the establishment of a proof of
concept in suitable animal models mimicking the human
phenotype as closely as possible. Furthermore, it will be
very important to get detailed information about the under-
lying mechanisms since this will result in further improvement
of the preventive approach. Finally, clinical studies are
required to prove the effectiveness of this approach,
particularly under long-term conditions. To reach this goal,
an interdisciplinary network must be established, combining
the expertise of epidemiologists and clinicians, together
with basic scientists from the fields of cellular biology,
immunology, biochemistry and molecular biology.
Perinatal nutrition and bone health in adults
Background to diet effects
Osteoporosis is a major and increasing cause of morbidity and
mortality in developed countries, and set to become worldwide
in the next few decades. The cost of treating fragility fractures
in the UK is £1·73 billion/year(217), close to that for treating
CVD (£1·75 billion)(218). The possibility that nutritional inter-
ventions in infancy could reduce the burden of adult degenera-
tive bone disease is therefore an important public health
issue(219). This section of the review will address three
questions:
(1) What are suitable measures or biomarkers of bone health
in human subjects?
(2) How well do these measures predict later outcome?
(3) What are the key early factors that influence later bone
health and can the effects of adverse early factors be
overcome later in life?
Measures or biomarkers of bone health in human subjects.
The ideal outcome measure, osteoporotic fracture, is for
obvious reasons rarely available, and bone biopsies cannot
be obtained in healthy children, precluding the use of histo-
logical or histomorphometric measures. In practice, therefore,
investigators are reliant on proxy measures that can be easily
obtained in healthy infants and children.
Bone mass or density (BMD) is generally obtained using
Dual X-ray Absorptiometry (DXA). In postmenopausal
women, DXA BMD is a significant predictor of a clinical out-
come, i.e. fracture risk. However, the predictive value of BMD
in children is much less clear and it cannot be automatically
assumed that BMD is the optimal DXA-derived parameter
to use in studies examining the effects of early life factors
on later bone health(220).
Quantitative computed tomography is used to make struc-
tural bone measurements, including volumetric bone density
of the peripheral skeleton (tibia and radius), quantitative com-
puted tomography is the best compromise between the need
for more detailed measures yet still with minimum radiation
exposure. Radial quantitative ultrasound measurements predict
fracture risk in adults(221), independently of BMD, and may
reflect aspects of bone structure not captured by DXA.
Bone is a dynamic tissue, constantly undergoing remodel-
ling, in which resorption is followed by bone formation at
the same site, allowing bone to adapt to biomechanical stresses
and for old or damaged bone to be replaced. Growing bone
also undergoes modelling, in which formation and resorption
are uncoupled and occur at different sites, with resorption
at endosteal surfaces and formation at periosteal surfaces.
Bone formation and resorption can be measured using a
variety of specific markers which are released into blood
or urine. Markers of bone formation include osteocalcin,
bone-specific alkaline phosphatase and amino-terminal
procollagen propeptides of type I collagen, released at different
stages of osteoblast proliferation and differentiation(222).
Markers for bone resorption are degradation products of
type 1 collagen that can be quantified in blood – plasma
carboxyterminal telopeptide 1 chain of type I collagen
(CTX) – or urine – N-telopeptides of type-I collagen (NTX)
and deoxypyridinoline normalised to creatinine. In adult
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populations, and in some paediatric diseases, these markers can
be useful clinical tools for monitoring the response to
treatment. However, levels of bone turnover markers are
influenced by many factors, including age, sex, time of day,
season and pubertal stage, which makes interpretation particu-
larly difficult in children. Furthermore, different methods and
assay kits produce different values for the same marker and
cannot be used interchangeably. Bone turnover markers pro-
vide a qualitative assessment of bone metabolism and may
be informative when longitudinal measurements are made
under standardised conditions or when comparisons can be
made between randomised groups. They typically correlate
poorly with measurements of bone mass in children.
Epidemiological evidence for association
Bone mass measurements during childhood have been shown
to predict fracture risk over the subsequent 2 years(223) or
4 years(224). Not surprisingly, there are no longitudinal studies
relating measurements in childhood with outcome in the
same individual. Nevertheless, peak bone mass is generally
accepted to be a good predictor of osteoporosis risk. Using
computer modelling, Hernandez et al.(225) predicted that a
10 % increase in BMD would delay the development of osteo-
porosis (defined as BMD ,2·5 SD from the young adult mean)
by 13 years, whereas a similar change in age at menopause or
non-menopausal bone loss would only result in a delay of
2 years. There are no reliable data on the predictive value
of quantitative computed tomography measurements in child-
hood for later outcome, but it seems reasonable to extrapolate
the likely effects of observed changes in bone geometry
(especially those seen in later childhood or adolescence) on
bone strength to effects in later life. In contrast, it is more
difficult to predict the consequences of differences in bone
turnover markers in childhood for later bone health.
Critical developmental stage
A number of factors have been shown to result in increased
bone mass in the short term, during the period of intervention.
This may in itself have immediate outcome benefits for the
individual; for example, reducing short-term fracture risk.
However, to represent a potential preventative strategy against
osteoporosis, any such effect must be shown to persist after
the intervention has stopped, resulting in higher peak bone
mass and/or favourable effects on bone structure or bone turn-
over. This has received much less attention.
Studies in human subjects suggest that influences in
fetal life, infancy and possibly childhood may programme
skeletal growth trajectory and later bone health. Data from
the Southampton Women’s Study suggest lower maternal
fat stores, vigorous activity in late pregnancy, maternal
smoking and low maternal birth weight, all predict lower
neonatal bone mass(226). Mechanistic explorations suggest
the association between maternal fat stores and infant bone
mass can be explained by umbilical venous leptin(227). Both
cord leptin and IGF-1(228) closely predict neonatal skeletal
size. Maternal vitamin D insufficiency or deficiency (seen in
49 % of women) during late pregnancy was also associated
with reduced bone size and mineral mass in the offspring at
9 years(9).
Analyses in both historical and modern prospective cohorts
have shown that birth weight is positively associated with
later bone mass, via an effect on body and skeletal
size(229 – 232) and that more rapid growth during infancy and
childhood is associated with higher bone mass in later
life(233,234). Weight in infancy predicts adult bone mass inde-
pendently of adult lifestyle, possibly by programming of the
IGF-1/growth hormone axis(234). Importantly, data from retro-
spective historical cohorts suggest that differences in weight
at 1 year of age predict differences in proximal femoral
geometry (an independent predictor of hip strength and frac-
ture risk) in later adult life(235) and that increased linear
growth during childhood predicts a lower risk of osteoporotic
fracture(236).
Experimental evidence and mechanistic understanding
That infant nutrition could influence later bone health has also
been the subject of several studies. Breast-feeding was associ-
ated with higher bone mass in children born at term(231) and
our(253) data suggest a similar beneficial effect of human
milk on peak bone mass in subjects born preterm. In our
experimental studies, in infants randomly assigned to diet
during early postnatal life, children born preterm and random-
ised to lower nutrient diets showed biochemical evidence of
increased bone formation later in childhood(237). In the same
cohort, those who developed (usually silent) metabolic bone
disease due to inadequate early intake of Ca and P were
shorter at 8–12 years, suggesting adverse programming of
linear growth(238). Conversely, nutritional interventions later
in childhood have less convincing long-term effects. While
Ca supplementation may have short-term benefits for bone
mass, these are generally lost once the intervention is with-
drawn, and there is little evidence for a clinically relevant per-
sisting effect of childhood Ca supplementation on long-term
bone health(239). There are theoretical reasons why other
elements of the diet such as vitamin K, Zn, protein, Na or
fruit and vegetables might influence later bone health, but
very few studies have yet been conducted on specific
nutrients.
Weight-bearing physical activity has attracted increasing
interest as a potential modifiable determinant of peak bone
mass. A number of randomised intervention studies in children
and adolescents have demonstrated increased bone mass in
loaded bones during the period of increased activity. Collec-
tively, the results of these studies suggest that effects are
site specific, greatest for cortical bone and that interventions
may be most effective during puberty when bone growth is
most rapid. Although the majority of studies have used
DXA to measure bone mass, some have also reported higher
cortical cross-sectional area, cortical thickness and increased
parameters of bending strength, suggesting that weight-
bearing exercise may have benefits for bone structure and
bone mass. Follow-up of individuals who have participated
in intervention trials is limited but two studies have
demonstrated effects persisting after the intervention ceased
on hip bone area and bone mineral content(240) and tibial
periosteal circumference(241). In some studies, the effect of
weight-bearing exercise was seen only in subjects with the
highest Ca intakes(241,242).
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Conclusion and future directions
In conclusion, despite limitations in the range of available
measures for assessing later bone health, there is evidence
that osteoporosis risk may be at least partly modified by inter-
ventions during early life designed to optimise linear growth,
nutrition and weight-bearing activity. The ‘critical period’
during which bone health can be programmed may well
extend throughout childhood and adolescence while the skel-
eton is still growing. It is relevant to consider the likely prac-
tical relevance of the observed effect sizes. Later bone mass in
subjects who received breast milk was about 0·4 SD higher
than in those who received formula(231) – about 12 % of the
population variance. The effects of weight-bearing exercise
interventions on BMD are in the order of 3–5 %. While
there are difficulties and uncertainties inherent in extrapolating
bone mass data from children to adults, it has been calculated
that a 2–3 % increase in peak bone mass could reduce later
fracture risk by 10–20 %. Hence, available data suggest that
the effect sizes observed with early interventions may be of
a magnitude which could be potentially significant in public
health terms in reducing the burden of osteoporosis.
Conclusion
Metabolic imprinting/programming is an increasingly import-
ant concept that may prove to be the single most important
mode of successful dietary intervention to improve health.
While much of the effort has been concentrated towards
early life (pre and early postnatal) as the most significant
developmental stages, there is some evidence that, for certain
health endpoints, a longer/later intervention may also be
successful.
The key opportunities for interventions, which have been
outlined in this review, include obesity, CVD, bone health,
cognition, immune function and diabetes. These are health
endpoints for which observational/epidemiological evidence
for programming exists. Underpinning many of these and
taking them beyond epidemiology and observational studies
are the experimental intervention investigations that make
use of both human and animal subjects. Providing a mechan-
istic basis for many of the observed effects are the epigenetic
studies looking at specific molecular events that extend
beyond genetic polymorphisms and provide a programmable
and exquisite way of controlling gene expression and
subsequent phenotype.
There remains considerable gaps in the knowledge and
challenges, not least in the development of suitable systems
to test hypotheses but the ultimate goal will be in the con-
trolled and predictable beneficial manipulation of human
health at all life stages in the short-term dietary interventions
leading to long-term improvements in health.
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